Thorsten Derlin

List of Publications by Year
in descending order

125 papers	3,300 citations	182225 30 h-index	198040 52 g-index
127 all docs	127 docs citations	127 times ranked	4094 citing authors

#	Article	IF	Citations
1	Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging. Journal of Nuclear Cardiology, 2022, 29, 202-203.	1.4	2
2	Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.4	14
3	Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMAâ€targeted radioligand therapy. Prostate, 2022, 82, 86-96.	1.2	5
4	CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation. JACC: Cardiovascular Imaging, 2022, 15, 372-374.	2.3	17
5	[18F]DCFPyL PET/CT for Imaging of Prostate Cancer. Nuklearmedizin - NuclearMedicine, 2022, 61, 240-246.	0.3	12
6	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ^{18}F-DCFPyL. Molecular Imaging, 2022, 2022, 7056983.	0.7	6
7	Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome. Journal of Nuclear Medicine, 2022, 63, 1415-1423.	2.8	36
8	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. Molecular Imaging and Biology, 2022, , 1.	1.3	2
9	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. Journal of Nuclear Medicine, 2021, 62, 823-828.	2.8	32
10	18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Annals of Nuclear Medicine, 2021, 35, 132-138.	1.2	17
11	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 1094-1106.	0.4	23
12	High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. Journal of Nuclear Medicine, 2021, 62, 514-520.	2.8	11
13	Prostate-specific Membrane Antigen Positron Emission Tomographyâ€"detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. European Urology Focus, 2021, 7, 309-316.	1.6	34
14	Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. Theranostics, 2021, 11, 7984-7994.	4.6	22
15	Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT). Orphanet Journal of Rare Diseases, 2021, 16, 29.	1.2	4
16	Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. Diagnostics, 2021, 11, 504.	1.3	12
17	Assessment of Î³-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. Cancers, 2021, 13, 1516.	1.7	5
18	Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 664225.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3343-3344.	3.3	0
20	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. Frontiers in Oncology, 2021, 11, 640467.	1.3	11
21	Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4077-4088.	3.3	10
22	Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs. Diagnostics, 2021, 11, 1132.	1.3	2
23	PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy. Cancers, 2021, 13, 2938.	1.7	18
24	Value of PET imaging for radiation therapy. Nuklearmedizin - NuclearMedicine, 2021, 60, 326-343.	0.3	2
25	Value of PET imaging for radiation therapy. Strahlentherapie Und Onkologie, 2021, 197, 1-23.	1.0	16
26	Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography. Current Radiopharmaceuticals, 2021, 14, 173-183.	0.3	3
27	CD19-Targeted Immunotherapy Attenuates Vessel Wall Inflammation. JACC: Cardiovascular Imaging, 2021, 14, 1864-1866.	2.3	4
28	Prostate Cancer Theranostics. , 2021, , 1117-1130.		0
29	Validation of Automated Perfusion–Weighted Phase–Resolved Functional Lung (PREFUL)–MRI in Patients With Pulmonary Diseases. Journal of Magnetic Resonance Imaging, 2020, 52, 103-114.	1.9	39
30	^{18}F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics, 2020, 10, 1-16.	4.6	117
31	^{18}F-FDG PET/CT in Left-Ventricular Assist Device Infection: Initial Results Supporting the Usefulness of Image-Guided Therapy. Journal of Nuclear Medicine, 2020, 61, 971-976.	2.8	22
32	Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. European Heart Journal, 2020, 41, 3564-3575.	1.0	52
33	Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlentherapie Und Onkologie, 2020, 196, 1006-1017.	1.0	8
34	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2328-2338.	3.3	13
35	Influence of short–term dexamethasone on the efficacy of ^{177}Lu–PSMA–617 in patients with metastatic castration–resistant prostate cancer. Prostate, 2020, 80, 619-631.	1.2	20
36	Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 2020, 61, 1602-1606.	2.8	25

#	Article	IF	Citations
37	The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1. PLoS ONE, 2020, 15, e0232031.	1.1	18
38	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. BMC Cancer, 2020, 20, 362.	1.1	20
39	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. Frontiers in Cardiovascular Medicine, 2020, 7, 51.	1.1	16
40	Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracersâ€"Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. Journal of Clinical Medicine, 2019, 8, 1060.	1.0	20
41	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.3	42
42	Advanced imaging in pulmonary hypertension: emerging techniques and applications. International Journal of Cardiovascular Imaging, 2019, 35, 1407-1420.	0.7	23
43	Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 103, 95-104.	0.4	53
44	Comparison of 68â€‰Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. Strahlentherapie Und Onkologie, 2019, 195, 420-429.	1.0	19
45	Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro-Oncology, 2019, 21, 508-516.	0.6	32
46	Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T. Molecular Imaging and Biology, 2018, 20, 650-658.	1.3	22
47	PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 913-922.	3.3	34
48	Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. European Heart Journal, 2018, 39, 966-966.	1.0	6
49	Assessment of liver ischemia reperfusion injury in mice using hepatic T_2 mapping: Comparison with histopathology. Journal of Magnetic Resonance Imaging, 2018, 48, 1586-1594.	1.9	11
50	Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury. European Radiology, 2018, 28, 4455-4464.	2.3	7
51	Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. Clinical Nuclear Medicine, 2018, 43, e170-e177.	0.7	24
52	Extra-vascular findings in patients undergoing magnetic resonance angiography of the abdomen, pelvis and lower extremities: A retrospective study of 352 patients. Vascular, 2018, 26, 27-38.	0.4	2
53	Screening of extravascular findings in pulmonary embolism computer tomography: 397 patients with 1950 non-pulmonary artery findings. Vascular, 2018, 26, 99-110.	0.4	1
54	Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 303-310.	1.0	23

#	Article	IF	Citations
55	Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using ⁶⁸Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. Journal of Nuclear Medicine, 2018, 59, 266-272.	2.8	92
56	Molecular Imaging in Oncology Using Positron Emission Tomography. Deutsches Ärzteblatt International, 2018, 115, 175-181.	0.6	27
57	Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?. Frontiers in Cardiovascular Medicine, 2018, 5, 170.	1.1	3
58	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetium€99m€nanocolloid. Lasers in Surgery and Medicine, 2018, 50, 994-1001.	1.1	16
59	Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [68Ga]pentixafor PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1934-1944.	3.3	58
60	[177 Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. Lancet Oncology, The, 2018, 19, e372.	5.1	3
61	CXCR4-targeted therapy in breast cancer. Lancet Oncology, The, 2018, 19, e370.	5.1	8
62	Targeting Chemokine Receptor CXCR4 and Translocator Protein for Characterization of High-Risk Plaque in Carotid Stenosis Ex Vivo. Stroke, 2018, 49, 1988-1991.	1.0	8
63	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. Nature Reviews Urology, 2018, 15, 511-521.	1.9	61
64	Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 960-968.	3.3	70
65	Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT. Clinical Nuclear Medicine, 2017, 42, 563-564.	0.7	12
66	Incidental findings in cardiac magnetic resonance imaging: superiority of bSSFP over T1w-HASTE for extra-cardiac findings assessment. International Journal of Cardiovascular Imaging, 2017, 33, 1581-1587.	0.7	5
67	Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation. Journal of Nuclear Medicine, 2017, 58, 1831-1837.	2.8	38
68	Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, e286-e293.	0.7	49
69	Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. Journal of Nuclear Medicine, 2017, 58, 1962-1968.	2.8	120
70	Visualization of Posttraumatic Splenosis on Chemokine Receptor CXCR4-Targeted PET/CT. Clinical Nuclear Medicine, 2017, 42, e317-e318.	0.7	5
71	Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042. European Urology, 2017, 72, e98-e99.	0.9	0
72	68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma. Clinical Nuclear Medicine, 2017, 42, e210-e211.	0.7	9

#	Article	IF	Citations
73	68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Extra-adrenal Paraganglioma in a Case of Complete Carney Triad. Clinical Nuclear Medicine, 2017, 42, e527-e528.	0.7	4
74	68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangioendothelioma. Clinical Nuclear Medicine, 2017, 42, e478-e479.	0.7	11
75	PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using 68Ga-PSMA Ligand PET/CT. Clinical Nuclear Medicine, 2017, 42, e173-e174.	0.7	39
76	18F-FDG PET for Detection of Primary Tracheobronchial T-/Natural Killerâ€"Cellâ€"Derived Posttransplant Lymphoproliferative Disorder After Lung Transplantation. Clinical Nuclear Medicine, 2017, 42, 988-989.	0.7	5
77	68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. Nuclear Medicine and Molecular Imaging, 2017, 51, 314-322.	0.6	44
78	Prevalence and clinical significance of incidental extra-mammary findings in breast magnetic resonance imaging: A retrospective study of 1070 patients. Clinical Imaging, 2017, 45, 92-95.	0.8	2
79	68Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. Anticancer Research, 2017, 37, 1273-1280.	0.5	25
80	Molecular Imaging of Chemokine Receptor CXCR4 in Nonâ€"Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT. Clinical Nuclear Medicine, 2016, 41, e204-e205.	0.7	24
81	Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. World Journal of Urology, 2016, 34, 1239-1245.	1.2	3
82	MDCT of acute pancreatitis: Intraindividual comparison of single-phase versus dual-phase MDCT for initial assessment of acute pancreatitis using different CT scoring systems. European Journal of Radiology, 2016, 85, 2014-2022.	1.2	16
83	The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2360-2373.	3.3	46
84	Comparison of image quality and visibility of normal and abnormal findings at submillisievert chest CT using filtered back projection, iterative model reconstruction (IMR) and iDose 4 â„¢. European Journal of Radiology, 2016, 85, 1971-1979.	1.2	23
85	Evaluation of 68 Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2213-2219.	1.1	12
86	Multitracer Molecular Imaging of Paget Disease Targeting Bone Remodeling, Fatty Acid Metabolism, and PSMA Expression on PET/CT. Clinical Nuclear Medicine, 2016, 41, 991-992.	0.7	13
87	Nonneoplastic Neuroma After Radical Prostatectomy Is Not a Mimicker of Lymph Node Metastases on 68Gaâ€"PSMA Ligand PET/CT. Clinical Nuclear Medicine, 2016, 41, 785-786.	0.7	3
88	Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. Journal of Nuclear Medicine, 2016, 57, 1556-1559.	2.8	8
89	68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer. Strahlentherapie Und Onkologie, 2016, 192, 431-439.	1.0	56
90	68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. European Radiology, 2016, 26, 4345-4353.	2.3	73

#	Article	IF	Citations
91	A randomized, double-blind, crossover comparison of novel continuous bed motion versus traditional bed position whole-body PET/CT imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 711-717.	3.3	20
92	Re: Lars Budäus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016;69:393â€"6. European Urology, 2016, 70, e37-e38.	0.9	9
93	Reduced-dose abdominopelvic CT using hybrid iterative reconstruction in suspected left-sided colonic diverticulitis. European Radiology, 2016, 26, 216-224.	2.3	14
94	Value of 99mTc-Technegas SPECT/CT for Localization of Alveolar-pleural Fistulas. Nuclear Medicine and Molecular Imaging, 2016, 50, 164-165.	0.6	2
95	68Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent prior to radical prostatectomy in patients with prostate cancer.. Journal of Clinical Oncology, 2016, 34, e632-e632.	0.8	1
96	99mTc-HMPAO perfusion SPECT/CT in the diagnosis of brain death. Nuclear Medicine Review, 2016, 19, 22-23.	0.3	1
97	18fF-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. Clinical Nuclear Medicine, 2015, 40, 521-522.	0.7	2
98	Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT. PLoS ONE, 2015, 10, e0143305.	1.1	20
99	Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. JACC: Cardiovascular Imaging, 2015, 8, 1417-1426.	2.3	159
100	Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation. European Radiology, 2015, 25, 1229-1237.	2.3	13
101	Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 696-705.	3.3	16
102	18F-FDG PET/CT for Detection of Metachronous Hodgkinâ€™s Disease in Patients with Myelofibrosis. Nuclear Medicine and Molecular Imaging, 2015, 49, 76-77.	0.6	0
103	Perfusion Single Photon Emission Computed Tomography in a Mouse Model of Neurofibromatosis Type 1: Towards a Biomarker of Neurologic Deficits. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1304-1312.	2.4	7
104	Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1943-1944.	3.3	4
105	Diagnostic value of 18F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. Nuclear Medicine Review, 2015, 18, 35-36.	0.3	3
106	18F-FDG PET/CT for Staging and Detection of Extramedullary Organ Involvement in Chronic Myelomonocytic Leukemia. Clinical Nuclear Medicine, 2014, 39, 811-812.	0.7	7
107	99mTc-Methylene Diphosphonate Bone Scintigraphy Findings in Posttransplant Distal Limb Syndrome. Clinical Nuclear Medicine, 2014, 39, 646-647.	0.7	1
108	Detection of occult vertebral fractures by quantitative assessment of bone marrow attenuation values at MDCT. European Journal of Radiology, 2014, 83, 167-172.	1.2	16

#	Article	IF	Citations
109	Imaging of multiple myeloma: Current concepts. World Journal of Orthopedics, 2014, 5, 272.	0.8	67
110	Glioblastoma Multiforme Metastatic to the Bone. Clinical Nuclear Medicine, 2014, 39, 188-189.	0.7	2
111	Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. European Radiology, 2013, 23, 570-578.	2.3	87
112	99mTc-MDP SPECT/CT for Assessment of Condylar Hyperplasia. Clinical Nuclear Medicine, 2013, 38, e48-e49.	0.7	14
113	Intraindividual Comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the Detection of Adrenal Pheochromocytoma in Patients With Elevated Urine or Plasma Catecholamines. Clinical Nuclear Medicine, 2013, 38, e1-e6.	0.7	27
114	Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1. Clinical Nuclear Medicine, 2013, 38, e19-e25.	0.7	84
115	Synchronous Bronchioloalveolar and Squamous Cell Lung Cancer With Different 18F-FDG Avidity on PET/CT. Clinical Nuclear Medicine, 2012, 37, e255-e256.	0.7	7
116	Adrenal Epithelioid Angiosarcoma Metastatic to the Epicardium. Clinical Nuclear Medicine, 2012, 37, 914-915.	0.7	21
117	18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 493-500.	3.3	66
118	F-18 FDG PET/CT Findings of Aggressive NK-Cell Leukemia. Clinical Nuclear Medicine, 2011, 36, 932-933.	0.7	6
119	Münchhausen Syndrome Presenting as Fever of Unknown Origin. Clinical Nuclear Medicine, 2011, 36, 1129-1130.	0.7	3
120	Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function. Annals of Nuclear Medicine, 2011, 25, 586-591.	1.2	11
121	Correlation of Inflammation Assessed by ^{18}F-FDG PET, Active Mineral Deposition Assessed by ^{18}F-Fluoride PET, and Vascular Calcification in Atherosclerotic Plaque: A Dual-Tracer PET/CT Study. Journal of Nuclear Medicine, 2011, 52, 1020-1027.	2.8	175
122	Feasibility of ^{11}C-Acetate PET/CT for Imaging of Fatty Acid Synthesis in the Atherosclerotic Vessel Wall. Journal of Nuclear Medicine, 2011, 52, 1848-1854.	2.8	43
123	In Vivo Imaging of Mineral Deposition in Carotid Plaque Using ^{18}F-Sodium Fluoride PET/CT: Correlation with Atherogenic Risk Factors. Journal of Nuclear Medicine, 2011, 52, 362-368.	2.8	157
124	Abnormal F-18 Fluoride Uptake in Intracranial Meningiomas on PET/CT. Clinical Nuclear Medicine, 2010, 35, 806-807.	0.7	10
125	Feasibility of ^{18}F-Sodium Fluoride PET/CT for Imaging of Atherosclerotic Plaque. Journal of Nuclear Medicine, 2010, 51, 862-865.	2.8	237